Jordan Elm to Ischemic Attack, Transient
This is a "connection" page, showing publications Jordan Elm has written about Ischemic Attack, Transient.
Connection Strength
1.355
-
Newly Diagnosed Atrial Fibrillation After Transient Ischemic Attack Versus Minor Ischemic Stroke in the POINT Trial. J Am Heart Assoc. 2021 03 16; 10(6):e019362.
Score: 0.172
-
Efficacy of Clopidogrel for Prevention of Stroke Based on CYP2C19 Allele Status in the POINT Trial. Stroke. 2020 07; 51(7):2058-2065.
Score: 0.163
-
Disability After Minor Stroke and Transient Ischemic Attack in the POINT Trial. Stroke. 2020 03; 51(3):792-799.
Score: 0.159
-
Outcomes Associated With Clopidogrel-Aspirin Use in Minor Stroke or Transient Ischemic Attack: A Pooled Analysis of Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trials. JAMA Neurol. 2019 12 01; 76(12):1466-1473.
Score: 0.157
-
Assessment of the End Point Adjudication Process on the Results of the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial: A Secondary Analysis. JAMA Netw Open. 2019 09 04; 2(9):e1910769.
Score: 0.155
-
Risk for Major Hemorrhages in Patients Receiving Clopidogrel and Aspirin Compared With Aspirin Alone After Transient Ischemic Attack or Minor Ischemic Stroke: A Secondary Analysis of the POINT Randomized Clinical Trial. JAMA Neurol. 2019 07 01; 76(7):774-782.
Score: 0.153
-
Time Course for Benefit and Risk of Clopidogrel and Aspirin After Acute Transient Ischemic Attack and Minor Ischemic Stroke. Circulation. 2019 08 20; 140(8):658-664.
Score: 0.153
-
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. N Engl J Med. 2018 Jul 19; 379(3):215-225.
Score: 0.141
-
Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial: rationale and design. Int J Stroke. 2013 Aug; 8(6):479-83.
Score: 0.101